CCN2 and idiopathic pulmonary fibrosis: Consequently, FG‐3019 (Pamrevlumab), which is a humanized anti‐CCN2 monoclonal antibody, was used in clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF) in the USA.23